Endocrine Pharmacology — MCQs

A 75-year-old woman with diabetes is taking oral antidiabetic drugs. She goes without eating for 18 hours, and her serum glucose concentration is 48 mg/dL (hypoglycemic) upon arrival at the emergency department, where she is deemed to be in critical condition. Which of the following drugs most likely aggravated this fasting hypoglycemia?

Q296Easy

Which drug causes hypothyroidism?

Q297Medium

Regarding leflunomide in pregnancy, all are true except?

Q298Easy

Which of the following is an inhalational form of insulin?

Q299Easy

A patient receiving insulin and acarbose for diabetes mellitus developed hypoglycemia. Which of the following should be used for the treatment of hypoglycemia in this patient?

Q300Medium

Which antidiabetic medication is known to cause osteoporosis as an adverse drug reaction?

Endocrine Pharmacology Indian Medical PG Practice Questions and MCQs

Question 291: Which one of the following oral hypoglycemic agents is not an insulin secretagogue?

A. Gliclazide
B. Glimiperide
C. Repaglinide
D. Rosiglitazone (Correct Answer)

Explanation: **Explanation:** The classification of oral hypoglycemic agents (OHAs) is based on their mechanism of action. **Insulin secretagogues** are drugs that stimulate the pancreas to release insulin, whereas **insulin sensitizers** improve the body's response to existing insulin. **Why Rosiglitazone is the correct answer:** Rosiglitazone belongs to the **Thiazolidinedione (TZD)** class. It acts as an **insulin sensitizer** rather than a secretagogue. Its primary mechanism involves activating the **PPAR-γ (Peroxisome Proliferator-Activated Receptor gamma)** receptors in adipose tissue, muscle, and liver. This leads to increased transcription of genes involved in glucose uptake (like GLUT-4) and lipid metabolism, thereby reducing insulin resistance. It does not directly stimulate pancreatic beta cells to release insulin. **Analysis of incorrect options:** * **Gliclazide & Glimepiride (Options A & B):** These are **Sulfonylureas** (2nd and 3rd generation respectively). They act by closing the ATP-sensitive K+ channels on the pancreatic beta-cell membrane, leading to depolarization, calcium influx, and subsequent insulin secretion. * **Repaglinide (Option C):** This is a **Meglitinide** analogue. Like sulfonylureas, it is a secretagogue that closes K+ channels, though it binds to a different site and has a shorter duration of action (used for postprandial glucose control). **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects of TZDs:** Weight gain, edema, and increased risk of congestive heart failure (due to fluid retention). Rosiglitazone specifically has been linked to increased cardiovascular risk. * **Secretagogues and Hypoglycemia:** Because they stimulate insulin release regardless of blood glucose levels, Sulfonylureas carry a high risk of hypoglycemia. * **Drug of Choice:** Metformin (a Biguanide) is also an insulin sensitizer (via AMPK activation) and is the first-line treatment for Type 2 Diabetes.

Question 292: What is an important difference between leuprolide and ganirelix regarding their effect on gonadotropin secretion?

A. Ganirelix can be given orally.
B. Ganirelix immediately reduces gonadotropin secretion. (Correct Answer)
C. Ganirelix must be given in a pulsatile fashion.
D. Ganirelix initially stimulates the release of LH and FSH.

Explanation: ### Explanation The key difference between these two drugs lies in their mechanism of action at the GnRH receptor. **1. Why Option B is Correct:** * **Ganirelix** is a **GnRH Receptor Antagonist**. It works by competitive blockade of the GnRH receptors in the anterior pituitary. This results in an **immediate** and direct inhibition of LH and FSH secretion. * **Leuprolide**, conversely, is a **GnRH Receptor Agonist**. When given continuously, it initially stimulates the receptors (causing a "flare"), and only after 1–2 weeks does it cause downregulation and desensitization of the receptors, leading to a decrease in gonadotropins. **2. Why the Other Options are Incorrect:** * **Option A:** Both leuprolide and ganirelix are peptides; they are degraded by GI enzymes and must be administered **parenterally** (SC/IM). * **Option C:** **Pulsatile** administration is a characteristic of native GnRH (or Gonadorelin) used to *treat* infertility by stimulating FSH/LH. Ganirelix is used to *suppress* the LH surge. * **Option D:** This describes the "flare effect" seen with **Leuprolide** (GnRH agonist). Ganirelix, being an antagonist, does not cause an initial stimulation. ### NEET-PG High-Yield Pearls: * **Clinical Use:** Ganirelix and Cetrorelix are primarily used in **Controlled Ovarian Hyperstimulation (IVF)** to prevent a premature LH surge. * **Advantage of Antagonists:** Unlike agonists (Leuprolide), GnRH antagonists do not require co-administration of anti-androgens (like Flutamide) because there is no initial testosterone surge/flare. * **Degarelix:** Another GnRH antagonist used specifically for advanced prostate cancer to achieve rapid testosterone suppression.

Question 293: Which is the fastest calcium-lowering agent?

A. Calcitonin (Correct Answer)
B. Plicamycin
C. Etidronate
D. Zoledronate

Explanation: **Explanation:** The management of hypercalcemia depends on the severity of symptoms and the urgency of calcium reduction. **Why Calcitonin is the correct answer:** Calcitonin (specifically Salmon Calcitonin) is the **fastest-acting** calcium-lowering agent. It works within **2 to 4 hours** of administration. Its rapid onset is due to its direct action on osteoclasts, where it inhibits bone resorption, and its secondary effect of increasing renal calcium excretion. However, its use is limited by **tachyphylaxis** (rapidly diminishing response) after 24–48 hours due to the downregulation of calcitonin receptors. **Analysis of Incorrect Options:** * **B. Plicamycin (Mithramycin):** An older cytotoxic antibiotic that inhibits bone resorption. It takes about 24–48 hours to show effects and is rarely used today due to significant toxicity (thrombocytopenia, hepatic and renal toxicity). * **C. Etidronate:** A first-generation bisphosphonate. Like all bisphosphonates, it has a slow onset of action (2–4 days) because it requires incorporation into the bone matrix to inhibit osteoclast activity. * **D. Zoledronate:** A potent, third-generation intravenous bisphosphonate. While it is the **most effective** and preferred drug for long-term management of malignancy-associated hypercalcemia, its peak effect occurs only after **48–72 hours**. **NEET-PG High-Yield Pearls:** * **Drug of Choice (Initial):** Aggressive IV hydration with Normal Saline (0.9% NaCl) is the first step in treating hypercalcemic crisis. * **Most Potent/DOC for Malignancy:** Zoledronate (IV). * **Fastest Acting:** Calcitonin (useful for the "gap" before bisphosphonates kick in). * **Cinacalcet:** A calcimimetic used specifically for secondary hyperparathyroidism in CKD.

Question 294: Which of the following is NOT a second-generation sulfonylurea drug?

A. Glipizide
B. Gliclazide
C. Tolbutamide (Correct Answer)
D. Glibenclamide

Explanation: Sulfonylureas are insulin secretagogues used in the management of Type 2 Diabetes Mellitus. They are classified into two generations based on their potency and duration of action [1]. **Why Tolbutamide is the correct answer:** **Tolbutamide** belongs to the **First-generation** sulfonylureas [1]. These older agents (including Chlorpropamide, Tolazamide, and Acetohexamide) are characterized by lower potency, requiring higher milligram doses, and a higher risk of drug interactions compared to the newer generation [1], [2]. Tolbutamide specifically has a short duration of action and is primarily metabolized in the liver [3], [4]. **Why the other options are incorrect:** * **Glipizide (Option A):** A potent **Second-generation** sulfonylurea with a short half-life, making it a preferred choice in elderly patients to minimize the risk of prolonged hypoglycemia [1], [3]. * **Gliclazide (Option B):** A **Second-generation** agent known for its additional antioxidant properties and lower risk of hypoglycemia compared to glibenclamide. * **Glibenclamide (Option D):** Also known as Glyburide, this is a classic **Second-generation** drug [1]. It is highly potent but carries a significant risk of prolonged hypoglycemia, especially in patients with renal impairment [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** They block ATP-sensitive $K^+$ channels in pancreatic $eta$-cells, leading to depolarization, $Ca^{2+}$ influx, and insulin release [2]. * **Glimepiride:** Often classified as a **Third-generation** sulfonylurea due to its once-daily dosing and rapid onset. * **Side Effects:** Hypoglycemia (most common) and weight gain. * **Disulfiram-like reaction:** Most commonly associated with **Chlorpropamide** (1st Gen). * **Safety in Renal Failure:** **Gliquidone** is the sulfonylurea of choice in renal insufficiency as it is primarily excreted via bile.

Question 295: A 75-year-old woman with diabetes is taking oral antidiabetic drugs. She goes without eating for 18 hours, and her serum glucose concentration is 48 mg/dL (hypoglycemic) upon arrival at the emergency department, where she is deemed to be in critical condition. Which of the following drugs most likely aggravated this fasting hypoglycemia?

A. Acarbose
B. Glyburide (Correct Answer)
C. Metformin
D. Pioglitazone

Explanation: **Explanation:** The patient is presenting with severe fasting hypoglycemia, a classic side effect of **Sulfonylureas**. **1. Why Glyburide is Correct:** Glyburide is a second-generation sulfonylurea. Its mechanism of action involves binding to the **SUR1 subunit** of the ATP-sensitive $K^+$ channels in pancreatic beta cells. This leads to channel closure, cell depolarization, calcium influx, and the **insulin secretion regardless of blood glucose levels**. Because sulfonylureas act as "insulin secretagogues," they can cause profound and prolonged hypoglycemia, especially in elderly patients or those who skip meals (fasting). Glyburide, in particular, has long-acting metabolites that increase the risk of hypoglycemia in the elderly. **2. Why the Other Options are Incorrect:** * **Acarbose (Alpha-glucosidase inhibitor):** It acts locally in the gut to delay carbohydrate absorption. It does not stimulate insulin secretion and therefore does not cause hypoglycemia when used as monotherapy. * **Metformin (Biguanide):** It primarily decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. It is classified as an "euglycemic" agent because it does not stimulate insulin release. * **Pioglitazone (Thiazolidinedione):** It acts via PPAR-gamma receptors to increase insulin sensitivity in muscle and adipose tissue. Like metformin, it does not promote insulin secretion and carries a minimal risk of hypoglycemia. **NEET-PG High-Yield Pearls:** * **Sulfonylureas and Meglitinides** are the only oral classes that directly cause hypoglycemia by stimulating insulin release. * **Management:** Severe sulfonylurea-induced hypoglycemia that is refractory to dextrose can be treated with **Octreotide** (a somatostatin analog that inhibits insulin release). * **Renal Caution:** Glyburide should be avoided in patients with renal impairment due to the accumulation of active metabolites; **Glipizide** is preferred in such cases.

Question 296: Which drug causes hypothyroidism?

A. Carbamazepine
B. Lithium (Correct Answer)
C. Sulfasalazine
D. Methotrexate

Explanation: **Explanation:** **Lithium (Option B)** is a mood stabilizer used in bipolar disorder that frequently causes thyroid dysfunction. It induces hypothyroidism through multiple mechanisms: 1. **Inhibition of Iodine Uptake:** It interferes with the trapping of iodine by follicular cells. 2. **Inhibition of Thyroid Hormone Release:** This is the most significant mechanism; lithium inhibits the proteolytic cleavage of thyroglobulin, preventing the release of $T_3$ and $T_4$ (similar to the effect of high-dose iodine). 3. **Interference with Deiodination:** It may inhibit the peripheral conversion of $T_4$ to $T_3$. Up to 10–20% of patients on long-term lithium therapy develop goiter or clinical hypothyroidism. **Incorrect Options:** * **Carbamazepine (A):** While it can lower serum $T_4$ levels by inducing hepatic microsomal enzymes (increasing metabolism), it rarely causes clinical hypothyroidism as $TSH$ usually remains normal. * **Sulfasalazine (C):** Used in inflammatory bowel disease and RA; it does not have a documented inhibitory effect on the thyroid axis. * **Methotrexate (D):** An antimetabolite used in oncology and autoimmune diseases; it is not associated with thyroid dysfunction. **High-Yield NEET-PG Pearls:** * **Amiodarone** is another high-yield drug causing thyroid issues (can cause both hypothyroidism via the Wolff-Chaikoff effect and hyperthyroidism). * **Monitoring:** Patients on Lithium must have their **TSH levels** monitored every 6–12 months. * **Treatment:** Lithium-induced hypothyroidism is treated with Levothyroxine; the drug does not necessarily need to be discontinued if it is effectively managing the psychiatric condition.

Question 297: Regarding leflunomide in pregnancy, all are true except?

A. It can cause hydrocephalus and skeletal anomalies in the fetus.
B. It is a pyrimidine synthesis inhibitor.
C. Its active metabolite can be detected in plasma for up to 2 years after discontinuation.
D. It is used to treat Rheumatoid arthritis in pregnancy. (Correct Answer)

Explanation: **Explanation:** Leflunomide is a Disease-Modifying Antirheumatic Drug (DMARD) that acts by inhibiting **dihydroorotate dehydrogenase**, an enzyme essential for **de novo pyrimidine synthesis**. This leads to decreased T-cell proliferation and reduced inflammation. **Why Option D is the correct answer (The "Except" statement):** Leflunomide is strictly **contraindicated in pregnancy** (FDA Category X). It is highly teratogenic and is never used to treat Rheumatoid Arthritis in pregnant women. If a patient becomes pregnant while on the drug, an emergency washout procedure using **cholestyramine** is required to rapidly lower plasma levels. **Analysis of other options:** * **Option A:** Leflunomide is known to cause severe structural defects, including **hydrocephalus**, craniofacial defects, and **skeletal anomalies**, as demonstrated in animal studies and clinical reports. * **Option B:** This is the correct mechanism of action. By inhibiting pyrimidine synthesis, it arrests stimulated lymphocytes in the G1 phase of the cell cycle. * **Option C:** Leflunomide is a prodrug converted to its active metabolite, **teriflunomide (A77 1726)**. This metabolite undergoes extensive enterohepatic circulation and has a very long half-life (approx. 2 weeks). Consequently, it can take **up to 2 years** to reach plasma levels below 0.02 mg/L (the safe threshold for pregnancy) after stopping the drug. **High-Yield Clinical Pearls for NEET-PG:** * **Washout Protocol:** To accelerate elimination, **Cholestyramine** (8g, 3 times daily for 11 days) is used. * **Monitoring:** Periodic Liver Function Tests (LFTs) are mandatory due to the risk of **hepatotoxicity**. * **Pre-conception:** Both men and women should ensure drug levels are below 0.02 mg/L before attempting to conceive.

Question 298: Which of the following is an inhalational form of insulin?

A. Lispro
B. Afrezza (Correct Answer)
C. Humulin
D. Ultralente

Explanation: **Explanation:** **Afrezza** is the correct answer as it is currently the only FDA-approved **ultra-rapid-acting inhalational insulin**. It consists of a dry powder formulation of recombinant human insulin delivered via a thumb-sized inhaler. Upon inhalation, the powder dissolves in the alveolar fluid and is rapidly absorbed into the systemic circulation, reaching peak concentrations within 12–15 minutes, mimicking the first-phase insulin release. **Analysis of Incorrect Options:** * **A. Lispro:** This is a rapid-acting insulin analogue (modified at the B28 and B29 positions). It is administered via subcutaneous injection or insulin pumps, not inhalation. * **C. Humulin:** This is a brand name for biosynthetic human insulin. It is available as Humulin R (Regular/Short-acting) and Humulin N (NPH/Intermediate-acting), both of which are injectable. * **D. Ultralente:** This is an older, long-acting crystalline zinc insulin suspension. It has largely been replaced by modern long-acting analogues like Glargine and Degludec and is administered subcutaneously. **High-Yield Clinical Pearls for NEET-PG:** * **Contraindications:** Afrezza is strictly contraindicated in patients with chronic lung diseases such as **Asthma or COPD** due to the risk of acute bronchospasm. * **Monitoring:** Baseline **FEV1** (Forced Expiratory Volume) must be measured before starting therapy, at 6 months, and annually thereafter. * **Smoking:** It is not recommended in patients who smoke or have recently quit smoking (<6 months). * **Historical Note:** Exubera was the first inhalational insulin but was withdrawn from the market due to its bulky design and poor sales; Afrezza is the modern, compact alternative.

Question 299: A patient receiving insulin and acarbose for diabetes mellitus developed hypoglycemia. Which of the following should be used for the treatment of hypoglycemia in this patient?

A. Sucrose
B. Galactose
C. Glucose (Correct Answer)
D. Starch

Explanation: ### Explanation **Concept:** Acarbose is an **$\alpha$-glucosidase inhibitor** that acts in the brush border of the small intestine. It inhibits the enzyme responsible for breaking down complex carbohydrates (polysaccharides and oligosaccharides) into absorbable monosaccharides like glucose. When a patient on acarbose develops hypoglycemia, the standard treatment of oral sucrose (table sugar) or starch will be ineffective. This is because acarbose **delays the digestion and absorption** of these complex sugars, preventing a rapid rise in blood glucose levels during an emergency. **Why Glucose is Correct:** * **Glucose (Dextrose)** is a monosaccharide. It does not require breakdown by $\alpha$-glucosidase and is absorbed directly into the bloodstream. Therefore, it bypasses the inhibitory effect of acarbose and provides immediate correction of hypoglycemia. **Why Other Options are Incorrect:** * **A. Sucrose:** This is a disaccharide (glucose + fructose). It requires $\alpha$-glucosidase for hydrolysis. In the presence of acarbose, its absorption is significantly delayed. * **D. Starch:** This is a complex polysaccharide. Its digestion into simple sugars is the primary target inhibited by acarbose. * **B. Galactose:** While it is a monosaccharide, it is not the physiological sugar used to rapidly correct clinical hypoglycemia; the brain primarily utilizes glucose. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug Class:** Acarbose and Miglitol are $\alpha$-glucosidase inhibitors used to reduce **post-prandial hyperglycemia**. 2. **Side Effects:** The most common side effects are GI-related (flatulence, diarrhea, abdominal cramps) due to the fermentation of undigested carbohydrates by colonic bacteria. 3. **Emergency Rule:** Always advise patients on $\alpha$-glucosidase inhibitors to carry **glucose tablets or honey** (which contains glucose/fructose) rather than candy or cane sugar for hypoglycemic episodes. 4. **Contraindication:** These drugs should be avoided in patients with Inflammatory Bowel Disease (IBD) or intestinal obstruction.

Question 300: Which antidiabetic medication is known to cause osteoporosis as an adverse drug reaction?

A. Metformin
B. Glibenclamide
C. Pioglitazone (Correct Answer)
D. Acarbose

Explanation: **Explanation:** **Pioglitazone** belongs to the **Thiazolidinedione (TZD)** class of antidiabetic drugs. These agents act as agonists for the **PPAR-γ (Peroxisome Proliferator-Activated Receptor gamma)** receptor. While PPAR-γ activation improves insulin sensitivity, it has a significant impact on bone metabolism. In the bone marrow, mesenchymal stem cells can differentiate into either adipocytes or osteoblasts. PPAR-γ activation shifts this balance toward **adipogenesis** (fat cell formation) while inhibiting **osteoblastogenesis** (bone-forming cell formation). This leads to decreased bone formation, reduced bone mineral density, and an increased risk of fractures, particularly in postmenopausal women. **Analysis of Incorrect Options:** * **Metformin (Biguanide):** Generally considered bone-neutral or potentially bone-protective. Its primary side effects are gastrointestinal (diarrhea, abdominal cramps) and lactic acidosis. * **Glibenclamide (Sulfonylurea):** Works by stimulating insulin secretion from pancreatic beta cells. It is primarily associated with hypoglycemia and weight gain, not osteoporosis. * **Acarbose (Alpha-glucosidase inhibitor):** Acts locally in the intestine to delay carbohydrate absorption. Its side effects are limited to the GI tract (flatulence, bloating). **High-Yield Clinical Pearls for NEET-PG:** * **TZD Side Effects:** Weight gain, **fluid retention/edema** (contraindicated in NYHA Class III/IV heart failure), and increased risk of **bladder cancer** (specifically associated with Pioglitazone). * **Fracture Site:** Fractures associated with TZDs often occur in distal upper or lower limbs (humerus, radius, feet) rather than the typical hip or spine fractures seen in involutional osteoporosis. * **Other drugs causing Osteoporosis:** Glucocorticoids (most common), Heparin (long-term), Phenytoin, and Proton Pump Inhibitors (PPIs).

Practice by Chapter

Hypothalamic and Pituitary Hormones

Practice Questions

Thyroid Drugs and Antithyroid Agents

Practice Questions

Insulin and Oral Hypoglycemic Agents

Practice Questions

Adrenocorticosteroids

Practice Questions

Sex Hormones: Estrogens and Progestins

Practice Questions

Androgens and Anabolic Steroids

Practice Questions

Hormonal Contraceptives

Practice Questions

Drugs Affecting Calcium Metabolism

Practice Questions

Drugs for Osteoporosis

Practice Questions

Pharmacological Management of Obesity

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free